<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526834</url>
  </required_header>
  <id_info>
    <org_study_id>TESSCAR002</org_study_id>
    <nct_id>NCT04526834</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma</brief_title>
  <acronym>CERTAIN</acronym>
  <official_title>Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tessa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tessa Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous&#xD;
      CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with relapsed or refractory CD30-positive Non-Hodgkin Lymphoma who have failed&#xD;
      standard available therapies and who meet eligibility criteria will have blood drawn to&#xD;
      manufacture the CD30.CAR-T cells.&#xD;
&#xD;
      CD30.CAR-T cells will be infused once following the completion of lymphodepleting&#xD;
      chemotherapy with Bendamustine and Fludarabine.&#xD;
&#xD;
      Subjects will be closely monitored for DLT and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">March 2036</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and dose limiting toxicities (DLT) of autologous CD30.CAR-T and establish the recommended Phase dose</measure>
    <time_frame>Day 0 to 28 for DLT</time_frame>
    <description>Incidence of DLTs and occurrence of study related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacokinetics of autologous CD30.CAR-T</measure>
    <time_frame>Start of infusion of CD30.CAR-T (Day 0) until year 5</time_frame>
    <description>AUC (copies/ug DNA over time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Start of CD30.CAR-T (Day 0) until progressive disease or start of new cancer therapy, whichever comes first, up to one year</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Start of CD30.CAR-T (day 0) until progressive disease or death, whichever comes first, up to one year</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Start of CD30.CAR-T (Day 0) until progressive disease or death, whichever comes first, up to one year</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Primary Mediastinal Large B-Cell Lymphoma (PMBCL)</condition>
  <arm_group>
    <arm_group_label>CD30 positive NHL subtypes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)&#xD;
Dose Level 1&#xD;
Dose Level 2&#xD;
Dose Level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD30.CAR-T</intervention_name>
    <description>Bendamustine and Fludarabine (3 days)&#xD;
Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)&#xD;
Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)&#xD;
Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)</description>
    <arm_group_label>CD30 positive NHL subtypes</arm_group_label>
    <other_name>CD30-directed genetically modified autologous T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligibility is determined priori to leukapheresis. Patients must satisfy the following&#xD;
        criteria to be enrolled in this study:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Male or female patients who are 18-75 years of age&#xD;
&#xD;
          3. Histologically confirmed ALCL, PTCL- NOS, ENKTCL nasal type, DLBCL-NOS and PMBCL&#xD;
&#xD;
          4. Relapsed or refractory CD30-positive NHL who have failed all available standards of&#xD;
             therapy. Patients may or may not have received an autologous or allogeneic HSCT&#xD;
             CD30-positive tumor&#xD;
&#xD;
          5. At least 1 measurable lesion according to the Lugano Classification&#xD;
&#xD;
          6. ECOG PS of 0 to 1 or equivalent Karnofsky PS Anticipated life expectancy &gt;12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CNS involvement by malignancy&#xD;
&#xD;
          2. Inadequate laboratory abnormalities at screening:&#xD;
&#xD;
             Hgb ≤ 8.0 g/dL Total bilirubin &gt; 1.5 x ULN (&gt;2 x ULN for patients with Gilbert's&#xD;
             syndrome) AST and ALT ≥ 5 x ULN CrCL ≤ 45 mL/min (as measured by Cockcroft-Gault&#xD;
             equation) ANC ≤ 1000/uL Platelets ≤75,000/uL PR or INR &gt;1.5 x ULN aPTT&gt; 1.5 x ULN&#xD;
&#xD;
          3. Active uncontrolled bleeding or a known bleeding diathesis&#xD;
&#xD;
          4. Inadequate pulmonary function defined as pulse oximetry &lt; 90% on room air&#xD;
&#xD;
          5. Ongoing treatment with immunosuppressive drugs including calcineurin inhibitions,&#xD;
             TNFalpha, mTOR, etc or chronic systemic corticosteroids (&gt;10 mg/day prednisone or&#xD;
             equivalent for &gt;48 hours)&#xD;
&#xD;
          6. Received prior therapy of:&#xD;
&#xD;
             Anti-CD30 Ab based therapy within the previous 8 weeks Previous CD30.CAR-T&#xD;
             investigational product Bi-specific CD30 Ab within the previous 8 weeks Allogenic HSCT&#xD;
             in the last 180 days Autologous HSCT within 90 days&#xD;
&#xD;
          7. Active GVHD requiring immune suppression regardless of grade&#xD;
&#xD;
          8. HIV positive&#xD;
&#xD;
          9. Active HBV and/or HCV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sairah Ahmed</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Therapeutics</last_name>
    <phone>+65 62352129</phone>
    <email>clinicaltrials@tessacell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Mei, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Flinn, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Ramos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sairah Ahmed, MD</last_name>
      <phone>713-794-4374</phone>
      <email>sahmed3@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD30, r/r NHL, DLBCL, ALCL, ENKTCL, PMBCL, PTCL, adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

